Jubilant Pharmova reported RS 214 Crore’s net profit in Q4; FY21 Profit at RS 836 Crore
The drug company said it planned to issue capital expenditures of RS 700-800 Crore at the current fiscal at the addition of new high-speed charging and finish lines with lyophilizer on the Spokane (US) site and CRD expansion (research and development of service capacity contracts).
The Jubilant Pharmova drug firm on Friday reported Consolidated Net Profit Rs 214 Crore for the fourth quarter which ended on March 31, 2021. The company has posted a net profit of Rs 260 Crore in the January 2019-20 quarter.
Sales reached Rs 1,552 Crore for the fourth quarter while the same thing on Rs 1,497 Crore in the same period of FY20.
For all 2020-21 fiscal, the company reported the consolidated net income of Rs 836 Crore. It was Rs 898 Crore at FY20.
The latest sales of fiscal companies reached Rs 5,964...